Automated imaging reveals a concentration dependent delay in reversibility of cardiac myocyte hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 2, 2012, Pages 282-290

  Ryall, Karen A ^a   Saucerman, Jeffrey J ^a  

^a University of Virginia   (United States)

Author keywords

Adrenergic signaling; Automated imaging; Cardiac hypertrophy; Cardiac myocytes; Computational model

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; PHENYLEPHRINE; PRAZOSIN;

ALGORITHM; ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL STRUCTURE; CELL TRACKING; CONTROLLED STUDY; HEART HYPERTROPHY; HEART MUSCLE CELL; IMAGE ANALYSIS; IMAGE PROCESSING; INTRACELLULAR SIGNALING; MOLECULAR IMAGING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT;

ADRENERGIC AGONISTS; ANIMALS; CARDIOMEGALY; COMPUTATIONAL BIOLOGY; MICROSCOPY; MYOCYTES, CARDIAC; PHENYLEPHRINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84862874187     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.04.016     Document Type: Article

References (35)

1. Hill J.A., Olson E.N. Cardiac plasticity. N Engl J Med 2008, 358(13):1370-1380.
2. Mudd J.O., Kass D.A. Tackling heart failure in the twenty-first century. Nature 2008, 451(7181):919-928.
3. Koitabashi N., Kass D.A. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol 2011, 1-11.
4. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11(2):214-222.
5. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.-J., et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 2006, 103(49):18733-18738.
6. Moens A.L., Takimoto E., Tocchetti C.G., Chakir K., Bedja D., Cormaci G., et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117(20):2626-2636.
7. Zafeiridis A., Jeevanandam V., Houser S.R., Margulies K.B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998, 98(7):656-662.
8. Kuhn M., Voss M., Mitko D., Stypmann J., Schmid C., Kawaguchi N., et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc Res 2004, 64(2):308-314.
9. Birks E.J., George R.S., Hedger M., Bahrami T., Wilton P., Bowles C.T., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011, 123(4):381-390.
10. Lusis A.J., Weiss J.N. Cardiovascular networks: systems-based approaches to cardiovascular disease. Circulation 2010, 121(1):157-170.
11. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7(8):589-600.
12. Evans J.G., Matsudaira P. Linking microscopy and high content screening in large-scale biomedical research. Methods Mol Biol 2007, 356:33-38.
13. Bass G.T., Ryall K.A., Katikapalli A., Taylor B.E., Dang S.T., Acton S.T., et al. Automated image analysis identifies signaling pathways regulating distinct signatures of cardiac myocyte hypertrophy. J Mol Cell Cardiol 2012, 10.1016/j.yjmcc.2011.11.009.
14. Jentzsch C., Leierseder S., Loyer X., Flohrschütz I., Sassi Y., Hartmann D., et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol 2012, 52(1):13-20.
15. Prasad K.-M.R., Xu Y., Yang Z., Acton S.T., French B.A. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther 2011, 18:43-52.
16. Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 1979, 9(1):62-66.
17. Vincent L., Soille P. Watersheds in digital spaces: an efficient algorithm based on immersion simulations. IEEE Trans Pattern Anal Mach Intell 1991, 13(6):583-597.
18. Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., et al. Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006, 7(10):R100.
19. ATP channel opener diazoxide. J Mol Cell Cardiol 2004, 37:1063-1067.
20. Barron A.J., Finn S.G., Fuller S.J. Chronic activation of extracellular-signal-regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes. Biochem J 2003, 371:71-79.
21. Pediani J.D., Colston J.F., Caldwell D., Milligan G., Daly C.J., Mcgrath J.C. β-arrestin-dependent spontaneous α1a-adrenoceptor endocytosis causes intracellular transportation of α-blockers via recycling compartments. Mol Pharmacol 2005, 67(4):992-1004.
22. Wright C.D., Chen Q., Baye N.L., Huang Y., Healy C.L., Kasinathan S., et al. Nuclear α1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes. Circ Res 2008, 103(9):992-1000.
23. Levin M.C., Marullo S., Muntaner O., Andersson B., Magnusson Y. The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002, 277(34):30429-30435.
24. Staehelin M., Simons P., Jaeggi K., Wigger N. CGP 12177: a hydrophilic β-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 1983, 258(6):3496-3502.
25. Brahmadevara N., Shaw A.M., MacDonald A. α1-Adrenoceptor antagonist properties of CGP 12177A and other β-adrenoceptor ligands: evidence against β3- or atypical β-adrenoceptors in rat aorta. Br J Pharmacol 2004, 142(4):781-787.
26. Brahmadevara N., Shaw A.M., MacDonald A. Evidence against β3-adrenoceptors or low affinity state of β1-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 2003, 138(1):99-106.
27. Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997, 59(56):551-571.
28. Nishimura J., Kanaide H., Nakamura M. Binding of [3H]Prazosin to porcine aortic membranes: interaction of calcium antagonists with alpha-1 adrenoceptors. J Pharmacol Exp Ther 1986, 236(3):789-793.
29. Daly C.J., Milligan C.M., Milligan G., Mackenzie J.F., Mcgrath J.C. Cellular localization and pharmacological characterization of functioning alpha-1 adrenoceptors by fluorescent ligand binding and image analysis reveals identical binding properties of clustered and diffuse populations of receptors. J Pharmacol Exp Ther 1998, 286(2):984-990.
30. Mackenzie J.F., Daly C.J., Pediani J.D., McGrath J.C. Quantitative imaging in live human cells reveals intracellular α1-adrenoceptor ligand-binding sites. J Pharmacol Exp Ther 2000, 294(2):434-443.
31. Tadevosyan A., Maguy A., Villeneuve L.R., Babin J., Bonnefoy A., Allen B.G., et al. Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem 2010, 285(29):22338-22349.
32. Boivin B., Chevalier D., Villeneuve L.R., Rousseau E., Allen B.G. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 2003, 278(31):29153-29163.
33. Boivin B., Lavoie C., Vaniotis G., Baragli A., Villeneuve L.R., Ethier N., et al. Functional β-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res 2006, 71(1):69-78.
34. Berry J.M., Le V., Rotter D., Battiprolu P.K., Grinsfelder B., Tannous P., et al. Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ Res 2011, 109:407-417.
35. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flügel L., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010, 363(15):1397-1409.